<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharma on FinanClub</title>
    <link>https://finan.club/tags/pharma/</link>
    <description>Recent content in Pharma on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 10 Apr 2024 09:02:25 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharma/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>BMY</title>
      <link>https://finan.club/us/bmy/</link>
      <pubDate>Wed, 10 Apr 2024 09:02:25 +0000</pubDate>
      
      <guid>https://finan.club/us/bmy/</guid>
      <description>score:239
Chances: Bristol Myers Squibb&amp;rsquo;s Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated colorectal cancer. Bristol Myers wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.</description>
    </item>
    
  </channel>
</rss>
